Table 2.

Baseline characteristics

Baseline characteristics	Asymptomatic with treatment	Asymptomatic without treatment	p-value
	n (%)	n (%)
Total	19 (45)	23 (55)
Demographics and CF characteristics
Age, years (median (IQR))	19.2 (11.4–33.5)	20.2 (12.7–29.1)	0.86
Female sex	7 (37)	9 (39)	0.88
Homozygous DeltaF508	8 (42)	14 (61)	0.23
CF-related diabetes	7 (37)	6 (26)	0.45
Pancreatic insufficiency	19 (100)	21 (91)	0.49
CF centre			0.00
Gothenburg (n = 14)	0	14
Lund (n = 11)	9	2
Stockholm (n = 15)	10	5
Uppsala (n = 2)	0	2
Microorganisms
Chronic PsA colonization	8 (42)	3 (15)	0.06
Treatments
Inhaled antibiotics	9 (50)	12 (54)	0.78
Inhaled corticosteroids	2 (11)	8 (35)	0.08
Macrolides	5 (26)	3 (13)	0.43
Inhaled rhDNase	7 (37)	5 (22)	0.28
Lung function and other clinical parameters
ppFEV1 (mean ± SD)	76.1 ± 22.6	82.0 ± 24.3	0.45
ppFVC (median (IQR))	100.0 (79.2–104.7)	94.7 (86.5–107.2)	0.67
Number of IV-antibiotics (median (IQR))	1 (0–3)	1 (0–3.25)	0.84
Hospitalization days (median (IQR))	0 (0–3.5)	0 (0–2.25)	0.88
Total IgE (median (IQR))a	18.0 (9.1–88.5)	41.0 (10.7–55.3)	0.73
Eosinophils (median (IQR))b	0.2 (0.1–0.4)	0.2 (0.1–0.3)	0.58

Treated vs non-treated patients with asymptomatic A. fumigatus colonization

IQR Interquartile Range; PsA Pseudomonas aeruginosa. ppFEV1 percent predicted Forced Expiratory Volume in one second; ppFVC percent predicted Forced Vital Capacity

^an = 25

^bn = 26